Investors

ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.

Investor Information

11-13-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

November 2025 Corporate Presentation

Form 10Q for the period ended September 30, 2025

Recent News

12-24-25 ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

11-13-25 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

11-06-25 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025

View all press releases

Annual Meeting of Stockholders

Thursday, June 12, 2025 at 9:30 AM ET

Proxy Statement

Webcast

Our Core Technology

CEO Michael Brigham discusses ImmuCell’s core technology with Dr. Joseph H. Crabb former Chief Scientific Officer and VP of Product Development for ImmuCell and the developer of First Defense.

Download Transcript

Listen to Interview